StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Droxidopa

HCID 92974
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
23651-95-8
Standard-SMILES
N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
InChIKey
QXWYKJLNLSIPIN-JGVFFNPUSA-N
Summenformel
C9H11NO5
Durchschnittliche Molmasse
213,19 g/mol
Monoisotopische Masse
213,06372245

Überblick

Droxidopa is a serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension. It has a role as an antihypertensive agent, a prodrug and a vasoconstrictor agent. It is a L-tyrosine derivative and a member of catechols.

Namen und Bezeichner

Bevorzugter Name
Droxidopa
IUPAC
(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
Englischer Name
DROXIDOPA
Summenformel
C9H11NO5
Molmasse
213.19

Namen und Synonyme

droxidopa23651-95-8L-DOPSDOPS(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acidNortherathreo-DopaserineL-threo-DOPSL-ThreodopsL-dihydroxyphenylserinedroxidopumSM 5688
Weitere Namen anzeigen
L-threo-3,4-DihydroxyphenylserineDroxidopa (JAN)roxidopaDroxydopaDroxidopa>Droxidopa-13C6
L-threo-dihydroxyphenylserineL-Tyrosine, beta,3-dihydroxy-, threo-CHEBI:31524J7A92W69L7DTXSID6046422threo DOPSthreo-DOPS(-)-(2S,3R)-2-AMINO-3-(3,4-DIHYDROXYPHENYL)-3-HYDROXYPROPANOIC ACID

Datenbank-Bezeichner

CAS
23651-95-8、3916-18-5
PubChem CID
92974
DTXSID
DTXSID201017236
ChEMBL
CHEMBL2103827
ChEBI
CHEBI:31524
UNII
24A0V01WKS、J7A92W69L7
EC Number
223-480-5、688-528-3
Nikkaji
J22.085J

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-3,2
Polarare Oberfläche (TPSA)
124 Ų
H-Brücken-Donoren
5
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
3
Schwere Atome
15
Formalladung
0
Komplexität
235

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt
232 · 232-235° (dec); mp 229-232° (dec) (Ohashi)
Siedepunkt
549.8 · 549.8±50.0 °C(Predicted)
Dichte
1.608 · 1.608±0.06 g/cm3(Predicted)
storage temp.
-20 °C · -20°C
Löslichkeit
3 mg/mL · DMSO: ≥3mg/mL
Aggregatzustand
powder
pka
2.09 · 2.09±0.24(Predicted)
Farbe
white to tan
Merck
14 · 14,3457
Stabilität
Hygroscopic
InChI
InChI=1/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/s3
InChIKey
QXWYKJLNLSIPIN-WWXSATIUNA-N
SMILES
[C@H](C1C=CC(O)=C(O)C=1)(O)[C@H](N)C(=O)O |&1:0,10,r|
CAS Datenbank
23651 · 23651-95-8

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 6 Einträge

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

Gefahrenhinweise

Hazard Classes and Categories · 2 Einträge

Skin Irrit. 2 (100%)

Skin Irrit. 2 (100%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Liver test abnormalities have not been reported in patients taking droxidopa, but the agent has had limited clinical use. There were no episodes of clinically apparent liver injury reported in the preregistration trials of droxidopa, and since its approval there have been no published reports of droxidopa hepatotoxicity. Thus, liver injury from droxidopa is likely to be rare, if it occurs at all.

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Droxidopa

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Sicherheitsdaten

wgk
3
hs_code
29225090
RTECS-Nr.
VT9626010
risk_code
36/37/38
hazard_code
Xi
safety_code
26
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2STOT SE 3

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

C - Cardiovascular system

QC - Cardiovascular system

Pharmacodynamics · 1 Eintrag

Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension.

Mechanism of Action · 1 Eintrag

Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.

Biological Half-Life2-3 hours.
Metabolism/MetabolitesDroxidopa is metabolized by aromatic L-amino acid decarboxylase.
FDA Pharmacological Classification · 6 Einträge

J7A92W69L7

DROXIDOPA

Chemical Structure [CS] - Catecholamines

Physiologic Effects [PE] - Increased Blood Pressure

The physiologic effect of droxidopa is by means of Increased Blood Pressure.

DROXIDOPA

MeSH Pharmacological ClassificationAgents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
Absorption, Distribution and Excretion · 2 Einträge

Oral bioavailability is 90%.

Droxidopa is mainly excreted in the urine, with the main metabolite being 3-O-methyldihydroxyphenylserine.

Anwendungen · 2 Einträge

BeschreibungDroxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa added to existing levodopa/decarboxylase inhibitor therapy produces significant improvements in retropulsion, dysarthria and muscular rigidity refractory to other treatments; however, tremor was unaffected.

VerwendenThe L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian.

Ergänzende Hinweise

DefinitionChEBI: A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension

Zugehörige Reaktionen

6
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 343999
HRID 343999als Produkt
Reaktionsgleichung von HRID 344000
HRID 344000als Produkt
Reaktionsgleichung von HRID 408057
HRID 408057als Produkt
Reaktionsgleichung von HRID 1599185
HRID 1599185als Produkt
Reaktionsgleichung von HRID 1599186
HRID 1599186als Produkt
Reaktionsgleichung von HRID 1762768
HRID 1762768als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung